drugset / Trial / NCT03123588
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.
Timeline
- Start
- 2017-11-14
- Primary completion
- 2020-08-03
- Completion
- 2020-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Anagrelide | Small molecule | 1 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 10 mg | Oral |